The Science Behind ReCOGnAIze™
Peer-reviewed. Clinically validated. Published in Alzheimer's & Dementia 2026.
Developed at NTU LKCMedicine, Singapore.
The Publication
Alzheimer's & Dementia, 2026
ReCOGnAIze™ was validated in a peer-reviewed study published in Alzheimer's & Dementia — the world's leading dementia journal. The study achieved AUC 0.90 accuracy for detecting Vascular Mild Cognitive Impairment. DOI: https://doi.org/10.1002/alz.70992 . Lead author: Mohammed Adnan Azam, PhD Candidate, NTU LKCMedicine.
The Validation
AUC 0.90 — What It Means
AUC (Area Under the Curve) measures a test's ability to distinguish between those who have a condition and those who don't. An AUC of 0.90 is considered excellent in clinical practice. ReCOGnAIze™ achieves this for Vascular MCI — outperforming the widely used MoCA test in Southeast Asian populations.
The Institution
NTU Lee Kong Chian School of Medicine
Gray Matter Solutions is a spin-off from Nanyang Technological University's Lee Kong Chian School of Medicine (NTU LKCMedicine) — one of Southeast Asia's leading medical research institutions. ReCOGnAIze™ was developed and validated within the university's research infrastructure, ensuring clinical rigour from the ground up.
The Method
Validated Against Plasma Biomarkers
ReCOGnAIze™ was validated not just against clinical diagnosis, but against plasma biomarkers — pTau181, NfL, and GFAP — the same biological markers used in leading dementia research globally. This confirms that the app measures real neurological changes in the brain, not just task performance. It positions ReCOGnAIze™ at the same evidence standard as the latest generation of clinical-grade digital assessment tools.
As Featured In
CNAMoneyFM 89.3The Straits TimesNTU Innovation Port